Table 1.
Patient baseline characteristics
| Single fraction (1 × 8 Gy) n = 16 |
Multiple fractions (5-6 × 4 Gy) n = 26 |
P-value | Lytic n = 17 |
Blastic n = 8 |
Mixed n = 17 |
P-value | |
|---|---|---|---|---|---|---|---|
| Sexa | 0.5 | 0.02 | |||||
| Male | 12 (75%) | 16 (62%) | 7 (41%) | 7 (87%) | 14 (82%) | ||
| Female | 4 (25%) | 10 (38%) | 10 (59%) | 1 (13%) | 3 (18%) | ||
| Age, yrb | 0.8 | 0.03 | |||||
| Median (Range) | 68.5 (39-89) | 66 (52-85) | 62 (39-84) | 69 (61-75) | 70 (46-89) | ||
| Body weight, kgb | 0.5 | 0.5 | |||||
| Median (Range) | 75 (44-92) | 79 (57-106) | 73 (57-106) | 77.5 (44-83) | 84.5 (56-95) | ||
| Karnofsky Performance Scoreb | 0.1 | 0.5 | |||||
| Median (Range) | 80 (60-100) | 80 (60-100) | 80 (60-90) | 80 (70-90) | 80 (60-100) | ||
| Time since primary tumor diagnosis, yrb | 0.6 | 0.3 | |||||
| Median (Range) | 4.0 (0.4-17.6) | 3.0 (0.1-23.8) | 1.9 (0.1-23.8) | 5.9 (0.2-12.3) | 2.8 (0.4-17.6) | ||
| Time since first metastasis, yrb | 0.8 | 0.3 | |||||
| Median (Range) | 1.2 (0-7.3) | 1.0 (0.3-7.8) | 0.8 (0-7.8) | 2.6 (0-7.3) | 1.2 (0-5.4) | ||
| Primary tumorc | 0.6 | 0.004 | |||||
| Breast | 3 (19%) | 5 (19%) | 5 (30%) | 1 (13%) | 2 (12%) | ||
| Lung | 1 (6%) | 5 (19%) | 4 (23%) | 1 (13%) | 1 (6%) | ||
| Prostate | 9 (56%) | 10 (38%) | 1 (6%) | 6 (74%) | 12 (70%) | ||
| Otherd | 3 (19%) | 6 (23%) | 7 (41%) | 0 (0%) | 2 (12%) | ||
| Lesion typec | 0.2 | ||||||
| Lytic | 4 (25%) | 13 (50%) | |||||
| Blastic | 3 (19%) | 5 (19%) | |||||
| Mixed | 9 (56%) | 8 (31%) | |||||
| Affected femura | 1 | 0.8 | |||||
| Unilateral | 14 (87%) | 23 (89%) | 14 (82%) | 8 (100%) | 15 (88%) | ||
| Bilateral | 2 (13%) | 3 (11%) | 3 (18%) | 0 (0%) | 2 (12%) | ||
| Concurrent systemic therapyc | 0.6 | 0.2 | |||||
| No concurrent therapy | 1 (6%) | 5 (19%) | 5 (29%) | 1 (13%) | 0 (0%) | ||
| Systemic therapy+Bisphosphonates | 4 (25%) | 6 (23%) | 3 (18%) | 1 (13%) | 6 (35%) | ||
| Systemic therapy–Bisphosphonates | 10 (63%) | 12 (46%) | 7 (41%) | 5 (61%) | 10 (59%) | ||
| Bisphosphonates only | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Missing | 1 (6%) | 3 (12%) | 2 (12%) | 1 (13%) | 1 (6%) |
a
Tested with Fisher exact.
b
Tested with Mann-Whitney U for differences between single and multiple fractions and with Kruskal-Wallis for differences between lytic, blastic and mixed lesions.
c
Tested with Pearson χ2.
d
Other = Kidney, Rectum, Kahler's disease, Urethra, Cervix or aCUP (cancer of unknown primary origin).